11 Are the Cardiovascular (CV) Risk Reductions Seen with Empagliflozin in the EMPA-REG OUTCOME Trial Explained by Conventional CV Risk Factors?
Publication date: October 2017 Source:Canadian Journal of Diabetes, Volume 41, Issue 5, Supplement Author(s): Uli C. Broedl, David Fitchett, Ruth L. Coleman, Alastair M. Gray, Jyothis T. George, Hans J. Woerle, Bernard Zinman, Rury R. Holman
Source: Canadian Journal of Diabetes - Category: Endocrinology Source Type: research
More News: Canada Health | Cardiology | Cardiovascular | Diabetes | Empagliflozin | Endocrinology | Heart | Jardiance